WO 2015054280A1
· 2015
[cited by applicant]
WO 2015095825A1
· 2015
[cited by applicant]
Croteau et al; The Journal of Pediatrics, vol. 164, pp. 383-388; 2014.
[cited by examiner]
Adams et al; Pediatrics, vol. 137, Feb. 2, 2016, pp. 1-10.
[cited by examiner]
Adams, D. et al., “Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies”, Pediatrics, 137(2): e20153257, pp. 1-10 (Feb. 2016).
[cited by applicant]
Araujo, Aline N. et al., “Genome-Wide Copy Number Analysis in a Family with p.G533C RET Mutation and Medullary Thyroid Carcinonma Identified Regions Potentially Associated with a Higher Predisposition to Lynph Node Meta…
[cited by applicant]
Brouillard, P. et al., “Genetics of lymphatic anomalies”, J. Clin. Invest., 124: 898-904 (2014).
[cited by applicant]
Burrows, P.E., “Lymphatic anomalities are are associated with RASA1 gene mutations in mouse and man”, 45: 167-171 (2010).
[cited by applicant]
Faul, J.L. et al., “Thoracic lymphangionas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome”, Am. J. Respir. Crit. Care Med., 161: 1037-1046 (2000).
[cited by applicant]
Hashimoto, T. et al., “Membrane-mediated regulation of vascular identity”, Birth Defects Res. C Embryo Today, 108: 65-84 (2016).
[cited by applicant]
Joyce, S. et al., “The lymphatic phenotype in Noonan and Cardiofaciocutaneous syndrome”, Eur. J. Hum. Genet., 24: 690-696 (2016).
[cited by applicant]
Kawai, K. et al., “Tissue-specific Carcinogenesis in Transgenic Mice Expressing the RET Proto-Oncogene with a Multiple Endocrine Neoplasia Type 2A Mutation”, Can. Res., 60: 5254-5260 (2000).
[cited by applicant]
Kawasaki, J. et al., “RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity”, The Journal of Clinical Investigation, 124(6): 2774-2784 (2014).
[cited by applicant]
Kettleborough, R.N. et al., “A systematic genome-wide analysis of zebrafish protein-coding gene function”, Nature, 496: 494-497 (2013).
[cited by applicant]
Kume, T., “Specification of arterial, venous, and lymphatic endothelial cells during embryonic development”, Histol. Histopathol., 25: 637-646 (2010).
[cited by applicant]
Kurek, V.L. et al., “Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome”, Am. J. Hum. Genet., 90: 1108-1115 (2012).
[cited by applicant]
Li, Dong et al., “Whole Exome Sequencing Identifies EPHB4 as a Novel Cause of Autosomal Dominant Lymphangiomatosis”, ACMG Annual Clinical Genetics Meeting, Mar. 2015, pp. 1-2.
[cited by applicant]
Lindhurst, M.J. et al., “A mosaic activating mutation in AKT1 associated with the Proteus syndrone”, N. Engl. J. Med., 365: 611-619 (2011).
[cited by applicant]
Luks, V.L. et al., “Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA”, J. Pediatr., 166: 1048-1054, e1041-1045 (2015).
[cited by applicant]
Makinen, T. et al., PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature, Genes Dev., 19: 397-410 (2005).
[cited by applicant]
Sun, S. et al., Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling, Cancer Cell, 28: 758-772 (2015).
[cited by applicant]
Wassef, M., “Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies”, Pediatrics, 136: e203-214 (2015).
[cited by applicant]
International Search Report/Written Opinion, dated Jan. 22, 2018, issued in corresponding International Application No. PCT/US17/49453, filed Aug. 30, 2017.
[cited by applicant]
Alitalo, Kari et al., “Lymphangiogenesis in development and human disease,” Nature, vol. 438, No. 7070, 2005, pp. 946-953.
[cited by applicant]
Trenor, Cameron C. et al., “Complex lymphatic anomalies,” Seminars in Pediatric Surgery, vol. 23, No. 4, 2014, pp. 186-190.
[cited by applicant]
Lo et al., “Severe neonatal manifestations of Costello syndrome,” Journal of Medical Genetics, vol. 45, No. 3, 2008, pp. 167-171.
[cited by applicant]
Fabretto, Antonella et al., “Two cases of Noonan syndrome with severe respiratory and gastroenteral involvement and the SOS1 mutation F6231,” European Journal of Medical Genetics, vol. 53, No. 5, 2010, pp. 322-324.
[cited by applicant]
Morcaldi, G. et al., “Lymphodysplasia and Kras Mutation: a Case Report and Literature Review,” Lymphology, vol. 48, 2015, pp. 121-127.
[cited by applicant]
Revencu, Nicole et al., “RASA1 Mutations and Associated Phenotypes in 68 Families with Capillary Malformation-Arteriovenous Malformation,” Human Mutation, vol. 34, No. 12, 2013, pp. 1632-1641.
[cited by applicant]
Smeltzer, D.M. et al., “Primary lymphatic dysplasia in children: chylothorax, chylous ascites, and generalized lymphatic dysplasia,” European Journal of Pediatrics, vol. 145, 1986, pp. 286-292.
[cited by applicant]
Notice of Reasons for Rejection, issued Jul. 13, 2021, issued in corresponding Japanese Application No. 2019-511562, with English translation.
[cited by applicant]
Civallero, Monica et al., “Activity of BKM120 and BEZ235 against Lymphoma Cells,” BioMed Research International, vol. 2015, Article ID 870918, 2015, pp. 1-12.
[cited by applicant]
Martin-Almedina, Silvia et al., “EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis,” The Journal of Clinical Investigation, vol. 126, No. 8, Aug. 2016, pp. 3080-3088.
[cited by applicant]
Ricci, K. W. et al., “A Phase 2 Clinical Trial Assessing Efficacy and Safety of the Mtor Inhibitor Sirolimus in the Treatment of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease,” Am…
[cited by applicant]